premature%20ejaculation
PREMATURE EJACULATION
Premature ejaculation is a male sexual dysfunction characterized by short, easily stimulated ejaculation that occurs always or nearly always before or within one minute of vaginal penetration.
It is involuntarily controlled and causes negative personal consequences like distress, frustration and avoidance of sexual intimacy.
Exact etiology and risk factors are unknown.

Introduction

  • A male sexual dysfunction characterized by:
    • Short, easily stimulated ejaculation that occurs always or nearly always before or within about 1 minute of vaginal penetration or a clinically significant and bothersome reduction in latency time, often to about 3 minutes or less
    • Either present from the first sexual experience or following a new bothersome change in ejaculatory latency
    • Involuntarily controlled
    • Causes negative personal consequences eg distress, bother, frustration, avoidance of sexual intimacy and interpersonal difficulty
  • Most common male sexual dysfunction with prevalence not affected by age
    • More common in younger men

Etiology

  • Unknown exact etiology with few data to support the following suggested biological and psychological hypotheses including:
    • Anxiety
    • Penile hypersensitivity
    • 5-HT receptor dysfunction

Risk Factors

  • Risk factors include:
    • Genetic influences (lifelong PE)
    • Prostatic inflammation and chronic bacterial prostatitis (acquired PE)
    • Hormonal aberrations or thyroid hormone disorders
    • Poor overall health status and obesity
    • Psychological factors that may precipitate PE are historical factors (eg sexual abuse, attitude towards sex in the home), individual psychological factors (eg body image, depression, performance anxiety) or relationship factors (eg intimacy, anger)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.